首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 250 毫秒
1.
为增强表位疫苗的免疫原性,本研究将O型口蹄疫病毒(FMDV)VP1中编码T细胞表位肽(aa 21~aa 40)序列连接于猪细小病毒(PPV)VP2的5'端,并插入到杆状病毒供体质粒pFastBac HTA中,构建成重组转座载体pFastBac-FMDV-VP1-PPV-VP2,转化含有穿梭载体Bacmid的E.coli DH10Bac中,经蓝白菌落筛选获得重组杆状病毒表达质粒rBac-FMDV-VP1-PPV-VP2,转染昆虫草地夜蛾(Sf9)细胞,并在Sf9中进行了表达。电镜观察显示,表达的重组蛋白能够自我组装成病毒样颗粒rPPV∶VLP(FMDV)。用间接免疫荧光试验(IFA)、western blot分析表明,表达产物具有与PPV VP2天然蛋白相似的免疫原性。小鼠免疫实验证实,在低浓度FMDV抗原下能够产生特异性T淋巴细胞增殖反应;而且该病毒样颗粒能诱导机体产生抗FMDV特异性细胞免疫反应。  相似文献   

2.
为了研制广谱高效的A型口蹄疫新型多表位疫苗,根据GenBank数据库的A型代表毒株VP1序列设计并合成了VP1结构蛋白上的主要抗原表位DNA段,即135 aa~160 aa和200 aa~213 aa,与牛IgG重链恒定区编码基因连接,将合成的2个表位基因经Xho工、EcoR Ⅰ和BamH Ⅰ酶切后依次克隆到pET-30a(+)载体上,构建重组质粒pRE2IgG,将其转化到大肠埃希菌BL21(DE3)感受态细胞,以IPTG诱导表达融合蛋白pRE2IgG,对表达产物进行SDS-PAGE电泳分析,Western blot检测.结果显示,重组蛋白获得高效表达,并以包涵体形式存在,其分子质量约为60 ku,且能与抗A型FMDV阳性血清发生特异性反应,具有良好的反应活性.  相似文献   

3.
口蹄疫病毒(foot and mouth disease virus,FMDV)的结构蛋白VP1难以实现体外的高效表达。本研究为获得良好免疫原性的VP1蛋白,选用肝片吸虫Fh8小肽段作为新型融合表达标签,构建重组Fh8-VP1免疫原,以期获得大肠杆菌中的高效表达。分别合成VP1的20~40aa和129~169aa之间的核苷酸片段,并用2个甘氨酸(GG)连接2个片段,合成的核苷酸片段(ΔVP1)克隆入Fh8标签之后,构建重组菌BL21(DE3)/pColdⅠ-Fh8-ΔVP1,SDSPAGE分析蛋白表达形式,Western blot方法检测重组His-Fh8-ΔVP1的抗原性。结果显示,成功构建重组质粒BL21(DE3)/pColdⅠ-Fh8-ΔVP1,并在大肠杆菌BL21(DE3)中获得高效表达,且以包涵体形式存在于菌体蛋白,可与猪源FMDV阳性血清发生特异性反应。  相似文献   

4.
A型塞内卡病毒(SVA)是近年来新流行的一种传染性病原,与口蹄疫病毒(FMDV)具有相似的基因组结构,所致临床症状也十分相似。为了研发一种新型的基因工程活载体疫苗,用于预防塞内卡病毒感染和口蹄疫,以SVA全长感染性克隆pSVA-GX01为基础,在SVA 2A与2B基因之间插入O型FMDV的VP1基因,经双酶切及测序鉴定,成功获得了重组质粒pSVA-FMDV-VP1-O。将重组质粒转染BHK-21细胞,拯救获得重组病毒rSVA-FMDV-VP1-O,间接免疫荧光试验鉴定显示,该重组病毒可在细胞中表达O型FMDV的VP1蛋白。对该重组病毒进行体外生长增殖特性以及遗传稳定性分析表明,重组毒株和亲本毒株在BHK-21细胞上具有相似的增殖特性,插入的FMDV VP1基因可在细胞传代过程中稳定存在6代。研究结果为开发以塞内卡病毒为载体构建表达口蹄疫病毒VP1蛋白的重组基因工程活载体疫苗提供了参考。  相似文献   

5.
为建立兔出血症病毒(RHDV)的血清学检测方法,本实验通过生物信息学分析,将RHDV衣壳蛋白VP60的3个区域VP60-1(aa2-aa208)、VP60-2(aa174-aa425)和VP60-3(aa342-aa579)分别进行原核表达,获得了大小为42 ku、47.5 ku和45.6 ku的重组蛋白。经ELISA和western blot试验分析显示3种重组蛋白均能够被RHDV阳性血清识别,但VP60-1较VP60-2和VP60-3具有更好的反应原性,因此以表达的重组蛋白VP60-1作为包被抗原建立了RHDV间接ELISA抗体检测方法。结果显示,该方法具有较好的敏感性、特异性和重复性,对不同免疫期兔血清的检测结果与HI呈显著相关性。对临床样品的检测结果表明该ELISA方法比HI试验更敏感。本研究以VP60-1为包被抗原建立的ELISA方法可以用于RHDV疫苗的免疫评估。  相似文献   

6.
猪圆环病毒2型(porcine circovirus type 2,PCV2)Cap蛋白是病毒的主要结构蛋白,能诱导宿主产生特异性免疫应答。口蹄疫病毒(foot-and-mouth disease virus,FMDV)VP1蛋白是病毒的主要免疫原性蛋白,能刺激机体产生中和抗体。利用杆状病毒表面展示系统,将这2种病毒蛋白与猪CD40配体(CD40 ligand,CD40L)进行融合表达并展示在杆状病毒表面,构建了rv Ac-Cap、rv Ac-VP1和rv Ac-Cap-VP1 3种重组杆状病毒。通过SDS-PAGE和Western blotting检测3种重组杆状病毒感染的Sf9细胞总蛋白,证明3种融合蛋白成功表达。纯化的重组杆状病毒颗粒以1×108pfu/只的剂量免疫接种BALB/c小鼠,通过间接ELISA检测血清中Cap和VP1的抗体浓度,证明表面展示有Cap和VP1的重组杆状病毒能激发小鼠产生较高水平的抗体,与PCV2和FMDV商品化疫苗免疫组的抗体浓度差异不显著(P0.05),表明该重组杆状病毒具有较好的免疫原性。  相似文献   

7.
根据GenBank中公布的猪O型口蹄疫病毒(foot and mouth disease virus,FMDV)全基因合成了FMDV结构蛋白前体蛋白P1基因,同时设计了扩增FMDV结构蛋白VP0、VP1和VP3基因的引物。以P1基因为模板,分别经PCR扩增获得FMDV VP0、VP1和VP3基因。扩增产物克隆于Blunt载体中,酶切后将目的片段连接到原核表达载体SUMO中,构建重组表达质粒SUMO-VP0、SUMO-VP1和SUMO-VP3,将重组质粒转化大肠杆菌BL21(DE3)plysS进行诱导表达。经SDS-PAGE电泳可见融合蛋白均获得高效表达,融合蛋白表观分子质量分别约为55、48和40 ku。在IPTG浓度为1.0 mmol/L,温度为37 ℃,诱导5 h时融合蛋白表达量最大。Western blotting结果表明,融合蛋白均可被FMDV阳性血清识别,反应原性良好。  相似文献   

8.
为开发猪O型口蹄疫病毒(FMDV)病毒样颗粒(VLPs)基因工程亚单位疫苗,试验参考GenBank中登录的FMDV毒株基因序列(登录号:JN998085),设计针对VP1、VP2、VP3和VP4 4个基因片段的特异性引物,以O型FMDV O/MYA98/XJ/2010毒株的cDNA序列为模板,对目的基因进行PCR扩增;将获得的VP3、VP1和VP4、VP2基因片段分别插入2个杆状病毒供体质粒(pFastBacDual)的p10和pH双元启动子中,构建pFBD-VP3-VP1和pFBD-VP4-VP2 2个重组转座质粒;将验证正确的2个重组转座质粒分别转化含有穿梭载体(Bacmid)的大肠杆菌DH10Bac感受态细胞,获得2个重组杆粒rBacmid-VP3-VP1和rBacmid-VP4-VP2,经验证正确后,对其进行扩增和提取,将其分别转染Sf9贴壁昆虫细胞,构建2个重组杆状病毒rvAc-VP3-VP1和rvAc-VP4-VP2;2个重组杆状病毒共同感染悬浮培养的Sf9昆虫细胞,利用杆状病毒表达系统在昆虫细胞内对4个基因进行表达,目的蛋白通过间接免疫荧光试验(IFA)、SDS-PAGE、Western blotting及透射电镜(EM)进行检测。结果显示,本研究成功构建2株分别表达FMDV VP1、VP2、VP3和VP4 4个结构蛋白的重组杆状病毒;特异性抗体检测发现,4个蛋白VP1~VP4均成功表达,且具有良好的特异性反应;4个蛋白在Sf9昆虫细胞内能够完成自我组装,形成与天然病毒结构相似的VLPs,直径大小在25~30 nm。本研究利用共感染表达方式在Sf9昆虫细胞内成功制备出FMDV病毒颗粒,为开发高效安全的FMDV基因工程亚单位疫苗开辟了一条新思路。  相似文献   

9.
利用限制性酶切从重组质粒pShuttle-CMV-VP中得到猪O型口蹄疫病毒VP1(21-60)-(141-160)-(200-213)位氨基酸的基因。将此多抗原表位基因克隆至原核高效表达载体pET43.1 a(+),在E.coliBL21中用IPTG诱导表达了含有猪口蹄疫病毒多抗原表位的融合蛋白,并用镍柱亲和层析法获得了纯化蛋白。W estern-b lot结果表明融合蛋白可被猪O型口蹄疫病毒标准阳性血清所识别,从而为进一步研究FMDV多表位抗原的免疫特性和诊断方法奠定了基础。  相似文献   

10.
为在真核细胞中共表达猪圆环病毒2型(PCV2)Cap蛋白与猪O型口蹄疫病毒(FMDV)VP1蛋白,本研究将其各自编码基因克隆于杆状病毒双表达载体(pFastBacTMDual)中构建重组转移质粒(pFBD-Cap-VP1),转化至DH10BacTM感受态细胞中制备重组杆粒(rBacmid-Cap-VP1),并转染Sf21昆虫细胞,拯救出能够共表达PCV2-Cap和FMDV-VP1蛋白的重组杆状病毒(rBac-Cap-VP1)。SDS-PAGE和western blot检测结果表明,共表达的重组PCV2-Cap和FMDV-VP1蛋白产物的分子量分别为28 ku和30 ku,各占总蛋白含量的11.6%和3.4%,能够分别与PCV2和FMDV抗体发生特异性反应,表明共表达蛋白具有良好的反应原性。本研究为PCV2和FMDV基因工程二联亚单位疫苗的研制奠定了基础。  相似文献   

11.
Peste des petits ruminants (PPR) and foot-and-mouth disease (FMD) are both highly contagious diseases of small domestic and wild ruminants caused by the PPR virus (PPRV) and the FMD virus (FMDV). In this study, a recombinant PPRV expressing the FMDV VP1 gene (rPPRV/VP1) was generated and FMDV VP1 expression did not impair replication of the recombinant virus in vitro and immunogenicity in inducing neutralizing antibody against PPR in goats. Vaccination with one dose of rPPRV/VP1 induced FMDV neutralizing antibody in goats and protected them from challenge with virulent FMDV. Our results suggest that the recombinant PPRV expressing the FMDV VP1 protein is a potential dual live vectored vaccine against PPRV and FMDV.  相似文献   

12.
根据已经公布的O型口蹄疫病毒VP1基因序列,设计合成了1对VP1基因特异性引物,应用RT-PCR技术从O型口蹄疫病毒标准毒株扩增得到VP1基因,并将其克隆到原核表达载体pET-28a中,构建了重组原核表达质粒pET-28a-VP1,对重组表达质粒鉴定正确后,转化大肠埃希菌BL21进行诱导表达,SDS-PAGE和Western blotting检测结果表明,O型口蹄疫病毒VP1基因在大肠埃希菌BL21中得到了正常表达,所表达的融和蛋白与标准O型口蹄疫病毒阳性血清具有特异性抗原/抗体反应,说明该融和蛋白具有免疫学活性.  相似文献   

13.
SUMMARY Foot-and-mouth disease virus (FMDV) vaccines are used to protect animals against infection by the 7 FMDV serotypes composed of greater than 60 FMDV subtypes. Because of problems of both live attenuated and inactivated FMDV vaccines and also because of the very large market for an effective safe vaccine, research into other types of vaccines has been undertaken. One of the 4 virus structural proteins, VP1, is believed to be the main protein that stimulates virus neutralising antibodies and studies have concentrated on its potential as a subunit vaccine. Genetic engineering has been used to clone the VF1 gene of FMDV and VP1 synthesised from the cloned gene has been used in experimental vaccine studies. The studies in small numbers of cattle and pigs demonstrated that 2 vaccinations with genetically engineered VP1 could confer protection against FMDV challenge. However, there are a number of areas that need further research before such a genetically engineered vaccine could be used commercially. The use of chemically synthesised antigenic fragments of VP1 has recently been reported, and these synthetic fragments appear to be potentially better at producing immunity to FMDV than the whole genetically engineered VP1 protein, perhaps because of conformational problems in the presentation of whole VP1. Other possible future directions in the research and in the development of safe, effective FMDV vaccines are discussed. In conclusion, although very significant progress has been made in cloning FMDV-VP1 genes, we are still far from a genetically engineered VP1-FMDV subunit vaccine. In the meantime, properly inactivated and safety-tested FMDV vaccines will continue to be used and to be of benefit to the livestock industry in countries where foot-and-mouth is endemic or in combating introductions of the disease.  相似文献   

14.
牛口蹄疫病毒VP2结构蛋白抗体间接ELISA方法的建立   总被引:2,自引:0,他引:2  
为建立牛口蹄疫(FMD)抗体的检测方法,本研究将口蹄疫病毒(FMDV)的VP2基因,通过pPROEXTM HTb表达载体在大肠杆菌DH5α中表达,获得大小为35ku的重组VP2蛋白(rVP2),western blot证实rVP2可与FMDV5种血清型的牛阳性血清发生特异性反应。以纯化复性的rVP2为抗原建立了FMDVrVP2间接ELISA方法。重复性试验证实批内、批间变异系数均小于10%。特异性交叉试验表明,该抗原不与常见的其他7种牛病阳性血清发生交叉反应。检测非免疫无口蹄疫国家牛阴性血清的特异性为100%;检测感染血清敏感性为97.3%;检测O-AsiaⅠ的二价苗免疫牛血清,与4种商品化试剂盒比较,其符合率分别为69.0%、95.0%、90.4%和86.8%。实验结果表明建立的ELISA方法可以用于口蹄疫感染和免疫抗体检测。  相似文献   

15.
利用杆状病毒表达系统对AsiaⅠ型口蹄疫病毒(foot-and-mouth disease virus,FMDV)VP1基因在Sf9昆虫细胞中进行表达,为研究AsiaⅠ型FMDV VP1蛋白功能及建立AsiaⅠ型FMDV血清学诊断方法奠定基础。采用PCR方法从pGEM-T-Easy-AsiaⅠ型VP1质粒中扩增VP1基因,将其插入杆状病毒转座载体pFastBacHTA,构建的重组质粒pFastBacHTA-VP1再转入DH10Bac感受态细胞,经三重抗性与蓝白斑筛选,获得杆状病毒重组质粒Bacmid-VP 1,然后转染Sf9昆虫细胞。PCR鉴定证实VP1基因正确地插入到Bacmid中,成功构建了杆状病毒重组质粒Bacmid-VP1,SDS-PAGE和Western-blotting检测结果表明,VP1基因在Sf9昆虫细胞中表达出约26.5 ku的VP1蛋白。将可溶性表达的融合蛋白用Ni-NTA亲和层析方法进行纯化,通过ELISA分析,能特异性地检测出AsiaⅠ型口蹄疫病毒阳性血清。AsiaⅠ型FMDV VP1基因在杆状病毒表达系统中的成功表达为AsiaⅠ型FMDV VP1蛋白的抗原性及血清学抗体水平检测研究奠定了基础。  相似文献   

16.
口蹄疫病毒结构蛋白基因vp1的表达与应用研究   总被引:2,自引:0,他引:2  
体外克隆口蹄疫病毒vp1基因,构建重组表达载体pET28a-vp1。将此重组质粒转化到受体菌BL21(DE3)中,进行诱导表达,SDS-PAGE和蛋白质印迹分析表明,诱导5h后表达量达到最高,表达产物大小约为33Ku-40Ku,表达蛋白能与口蹄疫病毒阳性血清产生特异性免疫反应。经HPLC纯化后,以重组蛋白为抗原,建立检测VP1蛋白抗体的ELISA方法,检测猪牛血清样品,免疫抗体检测结果与口蹄疫液相阻断ELISA检测结果呈正相关,能反映出免疫抗体动态变化,对临床样品口蹄疫病毒血清抗体检测,两种方法有一定相关性,但不显著。所以以重组VP1蛋白为检测抗原的ELISA方法有望用于口蹄疫免疫抗体监测。  相似文献   

17.
The nucleotide sequence of the protein-coding region of foot-mouth-disease virus (FMDV) strain O/HK/2001 was determined and compared with the sequences of other FMDVs that were registered in GenBank. The protein-coding region was 6966 nucleotides in length and encoded a protein of 2322 amino acid residues. Comparison of the nucleotide sequence and its deduced amino acid sequence with those of other isolates indicated that O/HK/2001 belonged to the Cathay topotype. A genomic coding region nucleotide sequence phylogenetic tree of several FMDV-O isolates showed that O/HK/2001 was most closely related to FMDV isolates found in Taiwan during 1997, and especially shared significant similarity to HKN/2002, suggesting that the virus causing outbreaks in Hong Kong was genetically most-closely related to that causing an outbreak of type O in Taiwan. Mutations in O/HK/2001 were revealed, including frequent substitutions in the VP1 and L proteins, and deletions involving 10 amino acid residues in the 3A protein. This study was undertaken to assess the regional variation of prevalent FMDV type O viruses and to establish a sequence database for FMDV molecular epidemiological investigation.  相似文献   

18.
O型口蹄疫病毒VP1嵌合基因的构建及原核表达   总被引:9,自引:0,他引:9  
首先合成我国O型口蹄疫病毒2个疫苗毒株VP1基因的3个抗原袁位,与另外扩增的流行毒株VP1基因末端273bp片段相连,构建出O型VP1嵌合基因片段(VP1O)。然后,将VPIO基因连接到原核表达载体pET28a上,构建了重组表达质粒pET28a-VP1O,转化大肠杆菌BL21(DE3)进行诱导表达。SDS-PAGE电泳表明。VP1O基因在大肠杆菌中获得表达。Western blotting检测证实表达的VP1O蛋白具有良好的生物学活性。对表达蛋白通过包涵体洗涤的方法进行初步纯化,获得了较高纯度的VP1O蛋白。  相似文献   

19.
Epitope-based vaccines are always questioned for their cross-protection against the antigenically variable foot-and-mouth disease virus (FMDV). In this study, we proved the cross-protection effect of a multi-epitope vaccine incorporated with poly(I:C) against three topotypes of O type FMDV. A total of 45 naïve pigs were vaccinated with different doses of multi-epitope protein vaccine incorporated with poly(I:C). At 28 days post-vaccination, 45 vaccinated and 6 unvaccinated control pigs (two pigs for each group) were challenged with three topotypes of virulent O type FMDV, namely, O/Mya/98 (Southeast Asia topotype), O/HN/CHA/93 (Cathay topotype) and O/Tibet/CHA/99 (PanAsia topotype) strains. All unvaccinated pigs developed generalised FMD clinical signs. Results showed that all pigs (n = 15) conferred complete protection against the O/Mya/98 and O/HN/CHA/93 FMDV strains, 11 of which were protected against the O/Tibet/CHA/99 FMDV strain. The 50% protective dose values of the vaccine against the O/Mya/98, O/HN/CHA/93 and O/Tibet/CHA/99 FMDV strains were 15.59, 15.59 and 7.05, respectively. Contact challenge experiment showed that transmission occurred from the donors to the unvaccinated but not to vaccinated pigs. These results showed that vaccination with multi-epitope protein vaccine incorporated with poly(I:C) can efficiently prevent FMD in pigs.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号